Synthetic enzyme - PvP Biologics

Drug Profile

Synthetic enzyme - PvP Biologics

Alternative Names: KumaMax

Latest Information Update: 09 Jan 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator University of Washington
  • Developer PvP Biologics
  • Class Enzymes; Proteins
  • Mechanism of Action Gliadin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Coeliac disease

Most Recent Events

  • 05 Jan 2017 PvP Biologics and Takeda collaborate to develop synthetic enzyme for Coeliac disease
  • 20 Dec 2016 Preclinical trials in Coeliac disease in USA (PO)
  • 20 Dec 2016 PvP Biologics plans clinical trial for Coeliac disease in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top